Sensing of cell-associated HTLV by plasmacytoid dendritic cells is regulated by dense β-galactoside glycosylation

PLoS Pathog. 2019 Feb 28;15(2):e1007589. doi: 10.1371/journal.ppat.1007589. eCollection 2019 Feb.

Abstract

Human T Lymphotropic virus (HTLV) infection can persist in individuals resulting, at least in part, from viral escape of the innate immunity, including inhibition of type I interferon response in infected T-cells. Plasmacytoid dendritic cells (pDCs) are known to bypass viral escape by their robust type I interferon production. Here, we demonstrated that pDCs produce type I interferons upon physical cell contact with HTLV-infected cells, yet pDC activation inversely correlates with the ability of the HTLV-producing cells to transmit infection. We show that pDCs sense surface associated-HTLV present with glycan-rich structure referred to as biofilm-like structure, which thus represents a newly described viral structure triggering the antiviral response by pDCs. Consistently, heparan sulfate proteoglycans and especially the cell surface pattern of terminal β-galactoside glycosylation, modulate the transmission of the immunostimulatory RNA to pDCs. Altogether, our results uncover a function of virus-containing cell surface-associated glycosylated structures in the activation of innate immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines
  • Dendritic Cells / physiology*
  • Galactosides / metabolism
  • Glycosylation
  • HTLV-I Infections / immunology
  • HTLV-I Infections / metabolism*
  • Human T-lymphotropic virus 1 / immunology
  • Human T-lymphotropic virus 1 / pathogenicity
  • Human T-lymphotropic virus 2 / immunology
  • Human T-lymphotropic virus 2 / pathogenicity
  • Humans
  • Immunity, Innate / physiology
  • Interferon Type I / immunology
  • Interferon-alpha / immunology
  • Interferon-alpha / metabolism
  • Jurkat Cells
  • T-Lymphocytes / immunology
  • T-Lymphocytes / physiology

Substances

  • Cytokines
  • Galactosides
  • Interferon Type I
  • Interferon-alpha
  • beta-galactoside

Grants and funding

This work was supported by “Ligue Nationale contre le Cancer, équipe labélisée program” EL2013-3Mahieux to Dr Hélène Dutartre and Pr Renaud Mahieux; by ‘‘Agence Nationale pour la Recherche’’ (ANR-JCJC-EXAMIN), ‘‘Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales’’ (ANRS-AO 2016-01) and LabEx Ecofect (ANR-11-LABX-0048) of the “Université de Lyon”, within the program "Investissements d'Avenir" (ANR-11-IDEX-0007) to Dr Marlène Dreux, and by LabEx Ecofect (ANR-11-LABX-0048) of the “Université de Lyon”, within the program "Investissements d'Avenir" (ANR-11-IDEX-0007) to Dr François-Loïc Cosset. Sonia Assil’s PhD fellowship was sponsored by the French ministry and the “Ligue contre le Cancer”. Nicolas Futsch’s PhD fellowship was sponsored by the “Ligue contre le Cancer”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.